Tug Of War Over Promising Cancer Drug Candidate Drug Discovery: Structure error threatens existing patent and clinical trials
Tug Of War Over Promising Cancer Drug Candidate Drug Discovery: Structure error threatens existing patent and clinical trials
Tug Of War Over Promising Cancer Drug Candidate Drug Discovery: Structure error threatens existing patent and clinical trials
A promising anticancer agent about to enter human clinical trials is on the hook because of a chemical structure error discovered by scientists at Scripps Research Institute California. The patented compound, known as TIC10 or ONC201, is owned by the biotech firm…